tiprankstipranks
Bolt Biotherapeutics (DE:6LP0)
FRANKFURT:6LP0
Germany Market
6LP0
Bolt Biotherapeutics
RESEARCH TOOLSreports

Bolt Biotherapeutics (6LP0) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

6LP0 Analyst Ratings

Strong Buy
4Ratings
Strong Buy
3 Buy
1 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Bolt
Biotherapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

6LP0 Stock 12 Month Forecast

Average Price Target

€30.12
▲(481.40% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Bolt Biotherapeutics in the last 3 months. The average price target is €30.12 with a high forecast of €65.16 and a low forecast of €6.08. The average price target represents a 481.40% change from the last price of €5.18.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","35":"€35","66":"€66","19.5":"€19.5","50.5":"€50.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65.15552175,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€65.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.116330053333332,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€30.12</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.08118203,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.08</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,19.5,35,50.5,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.18,9.793501673076923,14.407003346153846,19.020505019230768,23.634006692307693,28.24750836538462,32.861010038461544,37.47451171153846,42.08801338461539,46.70151505769231,51.31501673076924,55.928518403846155,60.54202007692308,{"y":65.15552175,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.18,7.098179234871795,9.01635846974359,10.934537704615384,12.852716939487179,14.770896174358974,16.689075409230767,18.60725464410256,20.525433878974358,22.44361311384615,24.361792348717948,26.27997158358974,28.198150818461535,{"y":30.116330053333332,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.18,5.249321694615384,5.318643389230769,5.3879650838461535,5.457286778461539,5.526608473076923,5.595930167692307,5.665251862307692,5.734573556923077,5.803895251538462,5.873216946153846,5.94253864076923,6.011860335384616,{"y":6.08118203,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.18,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€65.16Average Price Target€30.12Lowest Price Target€6.08
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on DE:6LP0
Boris Peaker
JonesTrading
JonesTrading
―
Hold
―
Reiterated
06/25/26
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (NASDAQ: AQST), Revolution Medicines (NASDAQ: RVMD) and Bolt Biotherapeutics (NASDAQ: BOLT)
H.C. Wainwright Analyst forecast on DE:6LP0
Robert Burns
H.C. Wainwright
H.C. Wainwright
€6.08
Buy
17.40%
Upside
Reiterated
05/28/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Rodman & Renshaw Analyst forecast on DE:6LP0
Michael King
Rodman & Renshaw
Rodman & Renshaw
€19.11
Buy
268.96%
Upside
Initiated
05/28/26
Bolt Biotherapeutics initiated with a Buy at Rodman & RenshawBolt Biotherapeutics initiated with a Buy at Rodman & Renshaw
Lake Street Analyst forecast on DE:6LP0
Chad Messer
Lake Street
Lake Street
€65.16
Buy
1157.83%
Upside
Reiterated
05/13/26
Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Coherus Biosciences (CHRS)
Leerink Partners Analyst forecast on DE:6LP0
Daina Graybosch
Leerink Partners
Leerink Partners
€17.37→€5.21
Hold
0.63%
Upside
Reiterated
09/04/25
Leerink Partners Keeps Their Hold Rating on Bolt Biotherapeutics (BOLT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on DE:6LP0
Boris Peaker
JonesTrading
JonesTrading
―
Hold
―
Reiterated
06/25/26
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (NASDAQ: AQST), Revolution Medicines (NASDAQ: RVMD) and Bolt Biotherapeutics (NASDAQ: BOLT)
H.C. Wainwright Analyst forecast on DE:6LP0
Robert Burns
H.C. Wainwright
H.C. Wainwright
€6.08
Buy
17.40%
Upside
Reiterated
05/28/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Rodman & Renshaw Analyst forecast on DE:6LP0
Michael King
Rodman & Renshaw
Rodman & Renshaw
€19.11
Buy
268.96%
Upside
Initiated
05/28/26
Bolt Biotherapeutics initiated with a Buy at Rodman & RenshawBolt Biotherapeutics initiated with a Buy at Rodman & Renshaw
Lake Street Analyst forecast on DE:6LP0
Chad Messer
Lake Street
Lake Street
€65.16
Buy
1157.83%
Upside
Reiterated
05/13/26
Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Coherus Biosciences (CHRS)
Leerink Partners Analyst forecast on DE:6LP0
Daina Graybosch
Leerink Partners
Leerink Partners
€17.37→€5.21
Hold
0.63%
Upside
Reiterated
09/04/25
Leerink Partners Keeps Their Hold Rating on Bolt Biotherapeutics (BOLT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bolt Biotherapeutics

3 Months
Robert BurnsH.C. Wainwright
Success Rate
3/4 ratings generated profit
75%
Average Return
+1.80%
Copying Robert Burns's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +1.80% per trade.
1 Year
Robert BurnsH.C. Wainwright
Success Rate
0/4 ratings generated profit
0%
Average Return
-18.60%
Copying Robert Burns's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -18.60% per trade.
2 Years
Robert BurnsH.C. Wainwright
Success Rate
0/4 ratings generated profit
0%
Average Return
-18.60%
Copying Robert Burns's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -18.60% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6LP0 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
2
4
2
2
0
Buy
0
1
1
1
0
Hold
1
2
3
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
7
6
5
1
In the current month, 6LP0 has received 0 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 6LP0 average Analyst price target in the past 3 months is 30.12.
Each month's total comprises the sum of three months' worth of ratings.

6LP0 Financial Forecast

6LP0 Earnings Forecast

Next quarter’s earnings estimate for 6LP0 is -€2.94 with a range of -€3.82 to -€2.42. The previous quarter’s EPS was -€3.74. 6LP0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year 6LP0 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 6LP0 is -€2.94 with a range of -€3.82 to -€2.42. The previous quarter’s EPS was -€3.74. 6LP0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year 6LP0 has Performed in-line its overall industry.

6LP0 Sales Forecast

Next quarter’s sales forecast for 6LP0 is €433.94K with a range of €0.00 to €1.30M. The previous quarter’s sales results were €22.56K. 6LP0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year 6LP0 has Performed in-line its overall industry.
Next quarter’s sales forecast for 6LP0 is €433.94K with a range of €0.00 to €1.30M. The previous quarter’s sales results were €22.56K. 6LP0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year 6LP0 has Performed in-line its overall industry.

6LP0 Stock Forecast FAQ

What is DE:6LP0’s average 12-month price target, according to analysts?
Based on analyst ratings, Bolt Biotherapeutics’s 12-month average price target is 30.12.
    What is DE:6LP0’s upside potential, based on the analysts’ average price target?
    Bolt Biotherapeutics has 481.40% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Bolt Biotherapeutics a Buy, Sell or Hold?
          Bolt Biotherapeutics has a consensus rating of Strong Buy, which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Bolt Biotherapeutics’s share price target?
            The average share price target for Bolt Biotherapeutics is 30.12. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €65.16 ,and the lowest forecast is €6.08. The average share price target represents 481.40% Increase from the current price of €5.18.
              What do analysts say about Bolt Biotherapeutics?
              Bolt Biotherapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of Bolt Biotherapeutics?
                To buy shares of DE:6LP0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.